Bone mineral density effects of randomized regimen and nucleoside reverse transcriptase inhibitor selection from ACTG A5142.
about
Antiretroviral therapy: current drugsBone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy oCorrelates and Longitudinal Renal and Cardiovascular Implications of FGF23 Levels in HIV-Positive Individuals.Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study.The protease inhibitors and HIV-associated bone loss.Tenofovir alafenamide as part of a salvage regimen in a patient with multi-drug resistant HIV and tenofovir-DF-associated renal tubulopathy.Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiationPharmacogenetics of antiretroviral therapy.Bone Loss in HIV Infection.Different Impact Of Antiretroviral Drugs On Bone Differentiation In An In Vitro Model.Improvement of BMD after Switching from Lopinavir/R Plus Two Nucleos(T)ide Reverse Transcriptase Inhibitors to Lopinavir/R Plus Lamivudine: OLE-LIP Substudy.Fibroblast growth factor 23: associations with antiretroviral therapy in patients co-infected with HIV and hepatitis C.Vitamin D3 Supplementation Increases Spine Bone Mineral Density in Adolescents and Young Adults with HIV Infection Being Treated with Tenofovir Disoproxil Fumarate: A Randomized, Placebo-Controlled Trial.Endocrinological aspects of HIV infection.Emerging reverse transcriptase inhibitors for HIV-1 infection.A Review of Long-Term Toxicity of Antiretroviral Treatment Regimens and Implications for an Aging Population.
P2860
Q34085926-AC05A39A-19D5-4693-9B58-C98D9DC2DD93Q35000905-9A9F1682-FD56-41BD-A98D-1458BAA0BB56Q36016861-3DF15797-2DD0-4041-A9CC-1E6370F49D3DQ36030485-024DF807-804A-43B3-B906-7DF7B7CA99F0Q36818259-C8691573-2C2C-4997-9E41-D6DBE36BB706Q37242504-D1713FB6-8D3C-487C-A48F-E635D322DE36Q37247235-3F736620-AFC4-433A-B7CE-A17EDC1B96E8Q38221179-7CCE5B78-0D28-4006-AB1A-33FFDD2E57FCQ38835028-5C99C61B-13AB-4AF8-BF9E-2C3F077E0E2DQ38895284-4F4B24B7-7C66-48E6-B70D-D861F4FDA36BQ40695106-3B0C48D3-95CF-4F59-93D4-5AF846D243EAQ41033591-E85B1D69-43B8-471F-9D9E-BF276F4ED252Q46099287-C7394B37-1E42-4A8A-AF54-4C67AD1F18B6Q47219853-2EE6C9C3-19CA-49EF-A945-E9D160413727Q53686168-F1BF11FE-BE3F-4CAB-BA4A-BBA60729BC0DQ54211761-2B217A6D-7EA9-4715-92B6-EE2F58971A9B
P2860
Bone mineral density effects of randomized regimen and nucleoside reverse transcriptase inhibitor selection from ACTG A5142.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Bone mineral density effects o ...... tor selection from ACTG A5142.
@en
Bone mineral density effects o ...... tor selection from ACTG A5142.
@nl
type
label
Bone mineral density effects o ...... tor selection from ACTG A5142.
@en
Bone mineral density effects o ...... tor selection from ACTG A5142.
@nl
prefLabel
Bone mineral density effects o ...... tor selection from ACTG A5142.
@en
Bone mineral density effects o ...... tor selection from ACTG A5142.
@nl
P2093
P2860
P356
P1433
P1476
Bone mineral density effects o ...... itor selection from ACTG A5142
@en
P2093
Aids Clinical Trials Group A5142 Study Team
Michael D Hughes
Richard H Haubrich
Sharon A Riddler
P2860
P304
P356
10.1310/HCT1405-224
P577
2013-09-01T00:00:00Z